Skip to main content
Fig. 1 | Orphanet Journal of Rare Diseases

Fig. 1

From: Review and comparison of clinical evidence submitted to support European Medicines Agency market authorization of orphan-designated oncological treatments

Fig. 1

Number of patients (a) and cumulative duration of follow-up (b) in included studies. All treatments belonged to ATC class L (antineoplastic and immunomodulatory agents). For inclusion in the review, treatments were required to have received EMA authorization for orphan-designated conditions within the previous 7 years, and to be supported by comparative trials with at least one survival-based clinical endpoint. Duration of follow-up was estimated by multiplying the total number of patients in each study by the study duration, or from Kaplan-Meier curves if these data were not available. MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; OC, ovarian cancer; RCC, renal cell carcinoma; STS, soft tissue sarcoma

Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172